Search

Chemotherapy is a common treatment for acute myeloid leukemia, but patients often stop responding. Until now, not much was known about why.

… Friday, December 2, 2016 Summary Acute myeloid leukemia is usually treated with chemotherapy , but patients often stop responding to these drugs and develop resistance to them. Now MSK investigators are learning why that is the case. Highlights Acute myeloid leukemia is the most common acute leukemia

Even as a child, physician-scientist Veronica Rotemberg always knew that her future self would be wearing a lab coat. Learn more about her journey and research.

… Monday, April 29, 2024 Veronica Rotemberg, MD, PhD , Director of Dermatology Informatics Program at Memorial Sloan Kettering Cancer Center (MSK), and leader of her own lab at Memorial Hospital, is passionate about her patients, technology, and the future. She has been a member of the MSK faculty for

The three recipients of the 2023 Paul Marks Prize for Cancer Research will present their research at a symposium. Learn about the research of Mark Agnel Frederick Dawson, Cigall Kadoch, and Michelle Monje,

… Monday, March 18, 2024 The three recipients of the 2023  Paul Marks Prize for Cancer Research will present their research at a symposium to be held March 26, 2024. The prize was named in honor of the late  Paul A. Marks, MD , President Emeritus of Memorial Sloan Kettering Cancer Center (MSK). It recognizes

Get to know Florisela Herrejon Chavez, a cancer biology graduate student in the Gerstner Sloan Kettering School of Biomedical Sciences.

… Wednesday, March 25, 2020 Summary As part of Women’s History Month, we are profiling some of MSK’s star female graduate students and postdoctoral fellows training to be leaders in their fields. Florisela Herrejon Chavez is a graduate student in the Kharas lab  in the Sloan Kettering Institute. When and

On July 22, 2021, Memorial Sloan Kettering Cancer Center was prominently featured on NBC News/The Today Show about “How to Navigate Nation’s Top Hospitals.”

… Thursday, July 22, 2021 On July 22, 2021, Memorial Sloan Kettering Cancer Center was prominently featured on NBC News/The Today Show about “ How to Navigate Nation’s Top Hospitals .” The segment positioned MSK as a leader in cancer care while highlighting our specialized care and personal approach and

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Wednesday, November 18, 2020 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Craig Thompson Awarded Columbia Business School’s Deming Cup for Operational Excellence Craig B. Thompson, MD Craig B. Thompson, MD , President and CEO at MSK, was awarded Columbia

Researchers identify a compound that appears to eliminate tumor cells in a dish and in mice.

… Wednesday, June 19, 2019 Summary MSK researchers identified a new strategy for inhibiting RNA-binding proteins, which play a role in many cancers. Since 2012, Memorial Sloan Kettering cancer biologist Michael Kharas has focused on studying a family of proteins called Musashi. These proteins play a role

The findings will lead to more accurate diagnoses and, potentially, to better treatments.

… Friday, July 20, 2018 Summary Experts say the findings about this type of tumor will lead to more accurate diagnoses and, potentially, to better treatments. In recent years, there have been many advances in treating children with cancer, but brain tumors remain a major challenge. For many pediatric brain

Learn about how nutrition experts are helping people with cancer maintain a healthy diet both during and after treatment.

… Wednesday, March 28, 2018 Summary MSK researchers have shown the crucial role that a healthy diet plays in cancer recovery. They are now developing unique ways to help people who are having transplants maintain good nutrition. People who have stem cell and bone marrow transplants face many challenges

An international team of researchers led by Howard Scher, MD, Co-Chair of the Center for Mechanism Based Therapy and Head of the Biomarker Development Initiative at Memorial Sloan Kettering Cancer Center (MSK), has validated a biomarker that can predict whether people with metastatic castration-resistant prostate cancer (mCRPC) may live longer if they are treated with a taxane-based chemotherapy instead of a second targeted androgen receptor–signaling inhibitor (ARSi).

… Thursday, June 28, 2018 Bottom Line: An international team of researchers led by Howard Scher, MD , Co-Chair of the Center for Mechanism Based Therapy and Head of the Biomarker Development Initiative at Memorial Sloan Kettering Cancer Center (MSK), has validated a biomarker that can predict whether people